Reviewing Caribou Biosciences (NASDAQ:CRBU) and HCW Biologics (NASDAQ:HCWB)

Caribou Biosciences (NASDAQ:CRBU) and HCW Biologics (NASDAQ:HCWB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Volatility and Risk

Caribou Biosciences has a beta of 2.5, suggesting that its share price is 150% more volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500.

Institutional and Insider Ownership

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by insiders. Comparatively, 9.1% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Caribou Biosciences and HCW Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%
HCW Biologics	-83.03%	-262.33%	-34.90%

Earnings & Valuation

This table compares Caribou Biosciences and HCW Biologics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16 million	3.94	-$148.12 million	($1.08)	-0.38
HCW Biologics	$50,000.00	46.82	-$7.96 million	($27.60)	-0.04

HCW Biologics has lower revenue, but higher earnings than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Caribou Biosciences and HCW Biologics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1	4	1	1	2.29
HCW Biologics	1	0	1	0	2.00

Caribou Biosciences currently has a consensus price target of $4.50, indicating a potential upside of 997.56%. HCW Biologics has a consensus price target of $30.00, indicating a potential upside of 2,770.81%. Given HCW Biologics’ higher probable upside, analysts clearly believe HCW Biologics is more favorable than Caribou Biosciences.

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

About HCW Biologics

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.